Genocea Biosciences Inc (NASDAQ:GNCA) traded up 8.5% during mid-day trading on Friday . The stock traded as high as $0.90 and last traded at $0.89. 3,227,054 shares traded hands during mid-day trading, an increase of 144% from the average session volume of 1,321,469 shares. The stock had previously closed at $0.82.

Several equities research analysts recently issued reports on the company. Zacks Investment Research cut Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Piper Jaffray Companies reissued an “overweight” rating and issued a $5.00 target price on shares of Genocea Biosciences in a research note on Thursday, November 2nd. ValuEngine lowered shares of Genocea Biosciences from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th. Needham & Company LLC lowered shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Finally, Cowen reissued a “buy” rating and issued a $10.00 target price on shares of Genocea Biosciences in a research note on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. Genocea Biosciences currently has an average rating of “Hold” and an average price target of $6.25.

The company has a debt-to-equity ratio of 2.51, a current ratio of 1.55 and a quick ratio of 1.55. The company has a market capitalization of $25.60, a P/E ratio of -0.41 and a beta of 1.94.

Genocea Biosciences (NASDAQ:GNCA) last released its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.08). During the same period last year, the firm earned ($0.45) EPS. analysts forecast that Genocea Biosciences Inc will post -1.91 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GNCA. Schwab Charles Investment Management Inc. purchased a new position in Genocea Biosciences in the 2nd quarter worth approximately $257,000. Rhumbline Advisers purchased a new position in Genocea Biosciences in the 2nd quarter worth approximately $157,000. Bank of New York Mellon Corp lifted its stake in Genocea Biosciences by 594.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 84,119 shares of the biotechnology company’s stock worth $439,000 after purchasing an additional 72,008 shares in the last quarter. Teachers Advisors LLC purchased a new stake in shares of Genocea Biosciences during the 2nd quarter valued at approximately $268,000. Finally, TIAA CREF Investment Management LLC purchased a new stake in shares of Genocea Biosciences during the 2nd quarter valued at approximately $404,000. 34.69% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Genocea Biosciences (GNCA) Trading 8.5% Higher” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://theolympiareport.com/2018/01/19/genocea-biosciences-gnca-trading-8-5-higher.html.

About Genocea Biosciences

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.